EBVD Combination Chemotherapy Plus Low Dose Involved Field Radiation is a Highly Effective Treatment Modality for Early Stage Hodgkin's Disease-Reference-Cited by-同舟云学术

EBVD Combination Chemotherapy Plus Low Dose Involved Field Radiation is a Highly Effective Treatment Modality for Early Stage Hodgkin's Disease

Published:2000-01 Issue:1-2 Volume:37 Page:131-143
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Angelopoulou Maria K.,Vassilakopoulos Theodoros P.,Siakantaris Marina P.,Kontopidou Flora N.,Boussiotis Vassiliki A.,Papavassiliou Constantinos,Kittas Christos,Pangalis Gerassimos A.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428190009057636

Reference58 articles.

1. Controversies in the management of early stage Hodgkin's disease [see comments]

2. Hodgkin's Disease

3. The management of stage I--II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience

4. Treatment of stages I and II hodgkin's disease with three different therapeutic modalities

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic significance of lymphocyte-to-monocyte ratio in patients with classical Hodgkin lymphoma before and after receiving first-line chemotherapy;Współczesna Onkologia;2022

2. The Significance of PET/CT in the Initial Staging of Hodgkin Lymphoma: Experience Outside Clinical Trials;Anticancer Research;2017-10-03

3. Thioredoxin-1, chemokine (C-X-C motif) ligand-9 and interferon-γ expression in the neoplastic cells and macrophages of Hodgkin lymphoma: clinicopathologic correlations and potential prognostic implications;Leukemia & Lymphoma;2017-06-02

4. Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens;The Oncologist;2016-02-26

5. Topoisomerase II Expression as an Independent Prognostic Factor in Hodgkin's Lymphoma;Clinical Cancer Research;2008-03-15